Healio
Healio

Cushing's Syndrome Awareness

Healio spoke with experts about diagnosis, recent treatment advances and common comorbidities in both Cushing’s disease and, more generally, Cushing’s syndrome.

Choose a Section
  • Laurence Katznelson, MD
  • Maria Fleseriu, MD, FACE

    • Maria Fleseriu, MD, FACE

    In this video playlist, Maria Fleseriu, MD, FACE, professor of medicine and neurological surgery, and Pituitary Center director of Oregon Health and Science University, Portland, discusses:

    • the process of diagnosing Cushing’s syndrome, including screening, confirmation and localization;
    • recurrence rates in Cushing’s disease, which “could be as high as 35% after pituitary surgery during long-term follow-up”;
    • developments in the treatment of Cushing’s syndrome and Cushing’s disease, including the recent FDA approvals of osilodrostat (Isturisa, Recordati) and levoketoconazole (Recorlev, Xeris Biopharma);
    • common comorbidities seen with Cushing’s syndrome, such as cardiovascular complications and diabetes; and
    • the importance of increasing awareness of these conditions in the medical community.

     

    References:

    Fleseriu M, et al. Lancet Diabetes Endocrinol. 2019;doi:10.1016/S2213-8587(19)30313-4.

    Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021;doi:10.1016/S2213-8587(21)00235-7.

    Gadelha M, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac178.

    Pivonello R, et al. Front Endocrinol (Lausanne). 2022;doi:10.3389/fendo.2022.899616.

    Read more about

    recurrent cushing disease
    cushing's disease
    levoketoconazole
    osilodrostat